Histone deacetylases (HDACs) are a large family of epigenetic metalloenzymes that are
involved in gene transcription and regulation, cell proliferation, differentiation, migration, and …

Targeted protein degradation refers to the use of small molecules that recruit a ubiquitin
ligase to a target protein for ubiquitination and subsequent proteasome-dependent …

Histone deacetylase 6 inhibitors (HDAC6is) have been applied to certain cancer diseases
and more recently to central nervous system (CNS) disorders including Rett syndrome …

Histone deacetylase 6 (HDAC6) is an attractive drug development target because of its role
in the immune response, neuropathy, and cancer. Knockout mice develop normally and …

Breast cancer is the most common female malignancy in both the developed and
developing world. Doxorubicin is one of the most commonly used chemotherapies for breast …

Nonselective histone deacetylase (HDAC) inhibitors show dose-limiting side effects due to
the inhibition of multiple, essential HDAC subtypes that can be limited or prevented by …

Affinity-based ultrafiltration–mass spectrometry coupled with ultraperformance liquid
chromatography–quadrupole time-of-flight mass spectrometry was utilised for the structural …

Inhibition of histone deacetylase 6 (HDAC6) in the brain is a highly attractive therapeutic
target for the treatment of neurodegenerative diseases. The low blood–brain barrier …

In recent years, histone deacetylases (HDACs) have emerged as promising targets in the
treatment of cancer. The approach is to inhibit HDACs with drugs known as HDAC inhibitors …

HDAC8 plays crucial roles in biological processes, from gene regulation to cell motility,
making it a highly desirable target for therapeutic intervention. HDAC8 also has deacetylase …